The average R&D investment of domestic pharmaceutical companies has increased, and innovation is pressing the "acceleration button"!

As of now, the 2021 financial reports of listed companies have basically been disclosed, and at the same time, the R&D expenses of each company have been announced
.
From the perspective of R&D expenses, the average R&D investment of domestic pharmaceutical companies has increased, and corporate innovation has pressed the "acceleration button"
.
A number of pharmaceutical companies will invest more than 1 billion yuan in research and development in 2021
.
Among them, in the Hong Kong stock market, BeiGene's R&D investment in 2021 has approached 10 billion yuan, reaching 9.
282 billion yuan, a year-on-year increase of 4%
.
The R&D investment of Fosun Pharma, Sino Biopharmaceuticals, Zai Lab, and CSPC is not inferior, all of which are more than 3 billion yuan
.
Judging from the year-on-year increase, some pharmaceutical companies have seen a surge in R&D investment in recent years
.
For example, Clover, from 2019 to 2020, Clover’s R&D expenditure increased from 45.
799 million yuan to 228 million yuan, a year-on-year increase of 398%
.
By 2021, Clover's R&D expenses have reached 1.
826 billion yuan, a seven-fold increase from the same period last year
.
In addition, the R&D investment of Zai Lab, CanSino Bio, Lepu Bio, and Kintor also increased by more than 100% compared with 2020
.
The biopharmaceutical industry is a high-investment industry.
Under the background that pharmaceutical companies have increased their R&D investment, some companies have gained a lot
.
For example, Hengrui Medicine, in the first three quarters of 2021, Hengrui Medicine’s R&D investment has exceeded 4 billion yuan
.
After years of investment and accumulation, Hengrui's R&D innovation has ushered in a harvest period
.
It is reported that in addition to the 10 innovative drugs already on the market, Hengrui has more than 50 innovative drugs under clinical development, and more than 240 clinical trials are being carried out at home and abroad
.
And build a number of technology platforms with independent intellectual property rights, forming an echelon product pipeline
.
In addition to the traditional oncology field with obvious advantages, Hengrui Medicine has also comprehensively deployed in the non-tumor field, realizing the treatment of autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, respiratory diseases, blood diseases, and nervous system diseases.
Extensive coverage in other fields
.
However, there are also some companies that have not yet achieved profitability because of "spending money" a lot.

.
For example, Junshi Bio, an unprofitable listed innovative pharmaceutical company, in 2021, Junshi Bio’s research and development expenses will be 2.
069 billion yuan, an increase of more than 15% over the same period last year
.
The number of R&D personnel in the company is 896, and the proportion of R&D personnel has further increased to 32%
.
Judging from Junshi Bio's net profit, in 2021, Junshi Bio's non-net profit will be -880 million yuan, which is significantly narrower than that in 2020
.
According to the annual report, the core product of Junshi Bio is toripalimab.
In 2021, the annual sales revenue of this product is 412 million yuan, which is lower than the sales revenue in 2020.
The reason is that toripalimab continues to be included in 2020.
After the version of the National Medical Insurance Catalogue, the 2021 version of the National Medical Insurance Catalogue was newly added, and the price was further reduced.
The company compensated the price difference for all the distributors' inventory, which also had a certain impact on the current product revenue recognition
.
The same is true of Zejing Pharmaceutical.
In 2021, Zejing Pharmaceutical will achieve revenue of 201 million yuan, a year-on-year increase of 627%; net profit loss has expanded compared with the same period of the previous year
.
It is reported that the company's revenue growth is mainly due to the company's first class 1 new drug, donafenib tosylate tablets, which was approved for marketing in June 2021 and began to generate drug sales revenue
.
The main reason for the year-on-year increase in losses is that its new drugs have been on the market for a short period of time, and the annual R&D investment has increased year-on-year
.
In this regard, Zejing Pharmaceutical also stated that in the future, it will continue to invest more in pre-market expansion and academic promotion activities
.
From the perspective of the industry, deep plowing and meticulous work can usher in a long-term accumulation
.
At present, innovation has become a trend in the development of the pharmaceutical industry, and has also become a new growth engine for many companies
.
Under the long-term high-intensity R&D investment, it is believed that in the near future, domestic pharmaceutical companies are expected to harvest more, create more, and meet clinical needs
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.